Evan Seigerman
Stock Analyst at BMO Capital
(3.68)
# 831
Out of 4,734 analysts
138
Total ratings
49.45%
Success rate
7.35%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $427.89 | +21.53% | 14 | Dec 20, 2024 | |
| BIIB Biogen | Downgrades: Market Perform | $230 → $164 | $140.98 | +16.33% | 25 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $57.04 | +6.94% | 11 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $94 → $102 | $92.96 | +9.72% | 14 | Nov 7, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $73.47 | -29.22% | 12 | Oct 30, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $128 → $114 | $145.88 | -21.85% | 14 | Oct 17, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $1,001 → $1,101 | $742.35 | +48.31% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $60.52 | +15.66% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $28.34 | +41.14% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $11.85 | +237.55% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $687.80 | +14.57% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.58 | -3.10% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $274.81 | -11.58% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $6.61 | +81.68% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.64 | +125.23% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.52 | +1,676.32% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.00 | +900.00% | 3 | May 12, 2020 |
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $427.89
Upside: +21.53%
Biogen
Dec 20, 2024
Downgrades: Market Perform
Price Target: $230 → $164
Current: $140.98
Upside: +16.33%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $57.04
Upside: +6.94%
Gilead Sciences
Nov 7, 2024
Maintains: Outperform
Price Target: $94 → $102
Current: $92.96
Upside: +9.72%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $73.47
Upside: -29.22%
Neurocrine Biosciences
Oct 17, 2024
Maintains: Market Perform
Price Target: $128 → $114
Current: $145.88
Upside: -21.85%
Eli Lilly
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $742.35
Upside: +48.31%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $60.52
Upside: +15.66%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $28.34
Upside: +41.14%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $11.85
Upside: +237.55%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $687.80
Upside: +14.57%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.58
Upside: -3.10%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $274.81
Upside: -11.58%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $6.61
Upside: +81.68%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.64
Upside: +125.23%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.52
Upside: +1,676.32%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.00
Upside: +900.00%